Med2Date — Clinical Guidelines
Home Endocrinology Subclinical Hypothyroidism

Subclinical Hypothyroidism

Last updated 31 May 2026 · Endocrinology clinical guideline

📋 Key Information Summary

📋
  • Definition: Persistently elevated serum TSH (>4.0–5.0 mIU/L) with a normal free thyroxine (FT4) level.
  • Prevalence: Common, affecting 4–10% of the general population, increasing with age and in women.
  • Aetiology: Most commonly due to early Hashimoto's thyroiditis. Iodine status in Australia is generally adequate.
  • Key Risk: Associated with progression to overt hypothyroidism (~2–5% per year), dyslipidaemia, and potential increased cardiovascular risk, particularly with TSH >10 mIU/L.
  • Symptoms: Often asymptomatic. Non-specific symptoms (fatigue, weight gain) may be present but are not reliably diagnostic.
  • Diagnosis: Requires confirmation of elevated TSH on at least two occasions 6–12 weeks apart, excluding transient causes.
  • Treatment Indications: Consider levothyroxine for TSH >10 mIU/L, symptomatic patients, women planning pregnancy/pregnant, and those with high cardiovascular risk.
  • Treatment Goal: Normalise TSH (target 0.5–2.5 mIU/L) and alleviate symptoms, avoiding over-treatment.
  • First-Line Therapy: Levothyroxine (Oroxine®, Eutroig®) - low dose initiation (e.g., 25–50 mcg daily) with titration.
  • Monitoring: TSH every 6–8 weeks after initiation/dose change, then annually once stable.
  • Special Populations: Aggressive treatment in pregnancy (TSH target <2.5 mIU/L in T1). Caution in elderly/cardiac disease (start very low dose).
  • ATSI Considerations: Increased prevalence and barriers to specialist access require community-tailored management and monitoring support.

🎧 Audio Brief

The Subclinical Hypothyroidism Paradox

A short clinical audio briefing generated from this article — perfect for the commute or ward round.

Subclinical Hypothyroidism clinical infographic — pathophysiology, clinical clues, diagnosis, imaging, and management
Tap or click image to enlarge — Subclinical Hypothyroidism: pathophysiology, clinical clues, diagnosis, imaging, and management.
Subclinical Hypothyroidism infographic, full size

Introduction & Australian Epidemiology

Subclinical hypothyroidism (SCH) is a common biochemical abnormality characterised by an elevated serum thyroid-stimulating hormone (TSH) level in the presence of a normal free thyroxine (FT4) concentration. It represents a state of mild, compensated thyroid failure. While often asymptomatic, SCH has been associated with non-specific symptoms and adverse long-term health outcomes.

In Australia, the prevalence of SCH is estimated at 4–10% of the adult population, with higher rates in women (particularly older women) and in regions with historical iodine deficiency, although mandatory iodine fortification of bread (2009) has improved population iodine status. Data from the Australian Bureau of Statistics and AIHW indicate significant variation in management, highlighting the need for clear clinical guidance.

This guideline provides a framework for the investigation, risk stratification, and management of SCH in Australian primary care and specialist settings, aligning with contemporary evidence and local healthcare structures.

Epidemiology & Aetiology

Prevalence

Population-based studies, including Australian data, report a SCH prevalence of approximately 4–10%. Key determinants include:

  • Age: Prevalence increases with age, exceeding 15% in women over 60 years.
  • Sex: Female to male ratio is approximately 5:1.
  • Iodine Intake: Both deficiency and excess can be contributory. Australia's mandatory fortification programme has made severe deficiency rare.
  • Geography: Historical iodine-deficient areas (e.g., parts of Tasmania, Victorian Alps) may have higher rates.

Aetiology

The most common cause is autoimmune thyroiditis (Hashimoto's disease), identified by the presence of anti-thyroid peroxidase (anti-TPO) antibodies. Other causes include:

  • Iatrogenic: Post-radioactive iodine therapy, partial thyroidectomy, external neck irradiation.
  • Drug-induced: Amiodarone, lithium, immune checkpoint inhibitors, tyrosine kinase inhibitors.
  • Transient causes: Subacute thyroiditis recovery, non-thyroidal illness syndrome resolution.
ℹ️
Australian Note: Anti-TPO antibodies are present in 60–80% of Australians with SCH. Testing aids in confirming aetiology and predicting progression risk.

Clinical Implications & Risk

While many patients are asymptomatic, SCH is not benign. Key clinical implications encompass symptom burden, progression risk, and cardiovascular/metabolic associations.

Symptoms & Progression

Non-specific symptoms may include fatigue, cold intolerance, weight gain, constipation, and dry skin. Their correlation with TSH levels is poor. The annual risk of progression to overt hypothyroidism (low FT4) is approximately 2–5%, higher in those with positive anti-TPO antibodies and higher baseline TSH.

Cardiovascular & Metabolic Risk

Evidence links SCH, particularly with TSH >10 mIU/L, to:

  • Dyslipidaemia: Elevated LDL cholesterol and total cholesterol.
  • Atherosclerosis & CHD: Increased risk of coronary heart disease events and heart failure, especially in younger patients.
  • Diastolic Hypertension.
  • Non-alcoholic fatty liver disease (NAFLD).
⚠️
High-Risk TSH: A TSH persistently >10 mIU/L is associated with a significantly higher likelihood of cardiovascular events and progression. This is a key threshold for considering treatment.

Indications for Treatment

The decision to treat is individualised, weighing potential benefits against risks of over-treatment (e.g., atrial fibrillation, osteoporosis). Strong indications include:

1
TSH >10 mIU/L
Persistent elevation on two tests 6–12 weeks apart. Treatment is generally recommended.
2
Pregnancy or Pre-conception
Women with SCH who are pregnant or planning pregnancy require treatment to achieve trimester-specific TSH targets (see Special Populations).
3
Symptomatic Patients
Consider a 3–6 month therapeutic trial of levothyroxine for patients with TSH 5–10 mIU/L and persistent, attributable symptoms.
4
High Cardiovascular Risk
Patients with existing CVD, dyslipidaemia, or high calculated risk may benefit from treatment.
5
Goitre or Rising TSH Trend
Progressive TSH rise or presence of a goitre may favour treatment.

For asymptomatic patients with TSH 5–10 mIU/L and low cardiovascular risk, active surveillance (TSH monitoring every 6–12 months) is a reasonable strategy.

Management & Monitoring

First-Line Therapy: Levothyroxine

💊
Levothyroxine Sodium
Oroxine® · Eutroig® · Thyroxine Sodium (Generic)
Adult Dose (Initiation) 25–50 micrograms orally once daily. Start low (12.5–25 mcg) in elderly or cardiac disease.
Titration Increase by 12.5–25 mcg every 6–8 weeks based on TSH.
Typical Maintenance 50–125 mcg daily. Dose based on lean body weight (~1.6 mcg/kg).
Administration On an empty stomach, 30–60 minutes before breakfast. Separate from calcium, iron, PPIs by ≥4 hours.
Renal Adjustment No specific adjustment, but use with caution in severe impairment.
Hepatic Adjustment No specific adjustment, but monitor closely.
PBS Status ✔ PBS General Benefit
✅
Brand Consistency: Advise patients to maintain consistent brand (e.g., Oroxine® vs. Eutroig®) as bioequivalence can vary. Document the brand on the prescription.

Monitoring Protocol

6–8 Weeks
First TSH check after initiation or dose change. Assess clinical response and side effects.
6–8 Weeks (Repeat)
Repeat TSH if previous result was not at goal. Titrate dose accordingly.
6 Months
Once stable (TSH in target range), recheck TSH.
Annually
Annual TSH monitoring for stable patients. Review symptoms, compliance, and medication interactions.

Treatment Goal: Aim for TSH in the lower half of the reference range (approx. 0.5–2.5 mIU/L) in most adults. Avoid iatrogenic suppression (<0.5 mIU/L) due to risks of AF and osteoporosis.

Special Populations

🤰 Pregnancy & Pre-conception
Indication: Treat all pregnant women with SCH. TSH goals are trimester-specific.
TSH Target: <2.5 mIU/L in first trimester, <3.0 mIU/L in second/third trimester (use local lab ranges).
Dose: Increase levothyroxine by ~25–30% upon pregnancy confirmation. Monitor TSH every 4 weeks in T1/T2.
Postpartum: Return to pre-pregnancy dose and monitor 6 weeks postpartum.
👶 Paediatrics
SCH in children is often idiopathic. Treatment considered if TSH >10 mIU/L, positive antibodies, or symptoms/growth impairment.
Dose: ~2–3 mcg/kg/day for infants, lower per kg for adolescents. Refer to paediatric endocrinology.
🧓 Elderly (>70 years)
Caution. Age-related TSH rise is physiological. Treatment may not improve QoL and carries risks.
If treatment indicated, start very low (e.g., 12.5–25 mcg) and titrate slowly. Target TSH 4–6 mIU/L is often acceptable.
🩺 Renal Impairment
No formal dose adjustment, but metabolism may be altered. Monitor TSH closely.
In dialysis patients, interpretation of TFTs is complex; involve nephrology/endocrinology.
🛡️ Immunocompromised
Checkpoint inhibitors (e.g., pembrolizumab) can cause SCH. Monitor TFTs at baseline and before each cycle.
Treat as per standard indications; SCH can be a marker of more severe irAE.

Aboriginal and Torres Strait Islander Health Considerations

Aboriginal and Torres Strait Islander Health
Epidemiology
Data on SCH prevalence in ATSI populations are limited. Autoimmune thyroid disease may be under-diagnosed. Iodine status in remote communities requires monitoring.
Access to Care
Geographic isolation and limited specialist access are major barriers. Management should be supported by local Aboriginal Health Workers/Practitioners and telehealth endocrinology.
Cultural Safety
Diagnosis and management plans must be developed in partnership, considering health literacy, cultural beliefs about medication, and family/community support structures.
Monitoring Support
Leverage Aboriginal Community Controlled Health Organisations (ACCHOs) for regular pathology collection (TSH) and medication adherence support. Use long-term dispensing (LTD) where appropriate.
⚠️
Key Action: When managing SCH in ATSI patients, engage with the local ACCHO, utilise Closing the Gap PBS co-payment relief, and establish a shared care plan with clear follow-up pathways.

📚 References

  1. 1. Australian Institute of Health and Welfare (AIHW). Thyroid disease in Australia. Cat. no. PHE 243. Canberra: AIHW; 2020.
  2. 2. The Royal Australian College of General Practitioners (RACGP). Thyroid function tests – position statement. East Melbourne, Vic: RACGP; 2021.
  3. 3. Pearce SH, Brabant G, Duntas LH, et al. 2013 ETA Guideline: Management of Subclinical Hypothyroidism. Eur Thyroid J. 2013;2(4):215-228.
  4. 4. Lazarus J, Brown RS, Daumerie C, et al. 2014 European thyroid association guidelines for the management of subclinical hypothyroidism in pregnancy and in children. Eur Thyroid J. 2014;3(2):76-94.
  5. 5. National Health and Medical Research Council (NHMRC). Iodine supplementation for pregnant and breastfeeding women. NHMRC public statement. Canberra: NHMRC; 2010.
  6. 6. Biondi B, Cappola AR, Cooper DS. Subclinical Hypothyroidism: A Review. JAMA. 2019;322(2):153-160.
  7. 7. Chaker L, Bianco AC, Jonklaas J, Peeters RP. Hypothyroidism. Lancet. 2017;390(10101):1550-1562.
  8. 8. Australian Government Department of Health. The Australian Immunisation Handbook. (For vaccine considerations in autoimmune disease). Canberra.
  9. 9. The Endocrine Society of Australia (ESA). Position statement on the management of hypothyroidism. 2022.
  10. 10. Ngaosuwan K, Johnston DG, Godsland IF, et al. Increased Mortality in Subclinical Hypothyroidism: A Systematic Review and Meta-Analysis. J Clin Endocrinol Metab. 2021;106(11):e4607-e4617.
co-pay for eligible patients).
Pregnancy & maternal health
Antenatal screening for thyroid disease should be integrated into Aboriginal Community Controlled Health Organisation (ACCHO) maternal health programmes. Untreated hypothyroidism in pregnancy disproportionately impacts communities with limited access to early antenatal care.
Comorbidity burden
Higher rates of diabetes, cardiovascular disease, and chronic kidney disease in Aboriginal and Torres Strait Islander communities mean hypothyroid-related dyslipidaemia and cardiovascular risk require particularly active management. Integrating thyroid function testing into chronic disease management plans (MBS Item 721) is recommended.
Iodine status
Although Australia-wide mandatory iodisation has improved status, some Aboriginal and Torres Strait Islander communities — particularly in very remote areas — may have borderline iodine adequacy. Urinary iodine monitoring in these communities should be maintained.

📚 References

  1. 1. Chaker L, Bianco AC, Jonklaas J, Peeters RP. Hypothyroidism. Lancet. 2017;390(10101):1550–1562.
  2. 2. Garber JR, Cobin RH, Gharib H, et al. Clinical practice guidelines for hypothyroidism in adults: cosponsored by the American Association of Clinical Endocrinologists and the American Thyroid Association. Endocr Pract. 2012;18(6):988–1028.
  3. 3. Pearce SH, Brabant G, Duntas LH, et al. 2013 ETA guideline: management of subclinical hypothyroidism. Eur Thyroid J. 2013;2(4):215–228.
  4. 4. Alexander EK, Pearce EN, Brent GA, et al. 2017 guidelines of the American Thyroid Association for the diagnosis and management of thyroid disease during pregnancy and the postpartum. Thyroid. 2017;27(3):315–389.
  5. 5. RACGP. Red Book: Guidelines for preventive activities in general practice. 9th ed. East Melbourne: RACGP; 2018.
  6. 6. Australian Institute of Health and Welfare (AIHW). Aboriginal and Torres Strait Islander health performance framework. Canberra: AIHW; 2023.
  7. 7. Li Y, Teng D, Shi X, et al. Prevalence of diabetes recorded in mainland China using 2018 diagnostic criteria from the American Diabetes Association: national cross sectional study. BMJ. 2020;369:m997. [TSH population reference data]
  8. 8. Ross DS. Diagnosis of and screening for hypothyroidism. In: UpToDate, Cooper DS (Ed). Wolters Kluwer; 2024. Accessed June 2024.
  9. 9. NHMRC. National evidence-based guideline: diagnosis, management and prevention of congenital hypothyroidism. Canberra: NHMRC; 2019.
  10. 10. Wiersinga WM, Duntas L, Fadeyev V, Nygaard B, Vanderpump MP. 2012 ETA guidelines: the use of L-T4 + L-T3 in the treatment of hypothyroidism. Eur Thyroid J. 2012;1(2):55–71.
  11. 11. Pharmaceuticals Benefits Scheme (PBS). Levothyroxine sodium. Australian Government Department of Health. Available at: pbs.gov.au. Accessed June 2024.
  12. 12. Australian Government Department of Health. National Newborn Bloodspot Screening — Congenital Hypothyroidism. Available at: www.newbornscreening.gov.au. Accessed June 2024.